1. New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases
- Author
-
Marc D. Natter, Deborah Rothman, Mary Beth F. Son, Sara Barmettler, Mindy S. Lo, Jordan E Roberts, and Mei-Sing Ong
- Subjects
Adult ,Pediatrics ,medicine.medical_specialty ,Younger age ,Adolescent ,New onset ,Hypogammaglobulinemia ,Young Adult ,Rheumatology ,Agammaglobulinemia ,immune system diseases ,Rheumatic Diseases ,hemic and lymphatic diseases ,Odds Ratio ,medicine ,Humans ,Pharmacology (medical) ,Child ,Retrospective Studies ,business.industry ,Incidence (epidemiology) ,Confounding ,Retrospective cohort study ,medicine.disease ,Rituximab ,Vasculitis ,business ,medicine.drug - Abstract
Objective To investigate the incidence and risk factors for hypogammaglobulinaemia and infectious complications associated with rituximab treatment in childhood-onset rheumatic diseases. Methods We performed a single-centre retrospective study of patients (n = 85) treated at Boston Children’s Hospital (BCH) from 2009 to 2019. Study subjects included patients (ages 6–24 years) who received rituximab for the treatment of a childhood-onset rheumatic disease. Results New-onset hypogammaglobulinaemia developed in 23 (27.1%) patients within 18 months of rituximab induction treatment. Twenty-two patients (25.9%) developed at least one infectious complication in the 18 months following the first rituximab infusion; of these, 11 (50%) had serious infections requiring inpatient treatment. After adjusting for potential confounders, exposure to pulse corticosteroid therapy in the month prior to rituximab use was a significant predictor of both new-onset hypogammaglobulinaemia (odds ratio [OR] 3.94; 95% CI: 1.07, 16.0; P = 0.044) and infectious complications (OR 15.3; 95% CI: 3.04, 126.8; P = 0.003). Post-rituximab hypogammaglobulinaemia was the strongest predictor of serious infectious complications (OR 7.89; 95% CI: 1.41, 65.6; P = 0.028). Younger age at rituximab use was also a significant predictor of new-onset hypogammaglobulinaemia (OR 0.83; 95% CI: 0.70, 0.97; P = 0.021). Compared with other rheumatic diseases, patients with vasculitis had a higher likelihood of developing infectious complications, including serious infections. Conclusion Although rituximab was well tolerated in terms of infectious complications in the majority of patients with childhood-onset rheumatic diseases, a substantial proportion developed new-onset hypogammaglobulinaemia and infectious complications following treatment. Our study highlights a role for heightened vigilance of rituximab-associated hypogammaglobulinaemia and infections in paediatric patients with rheumatic conditions.
- Published
- 2021
- Full Text
- View/download PDF